Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. 2000

F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
Hospital de l'Esperança/Hospital del Mar/Hospital Central l'Aliança (Barcelona), Hospital la Fé (Valencia), Spain. E0037@imas.imim.es

Recently, a consensus International Prognostic Scoring System (IPSS) for predicting outcome and planning therapy in the myelodysplastic syndromes (MDS) has been developed. However, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities for which real prognosis at present is uncertain. The main aims of this study were to evaluate in an independent series the prognostic value of the IPSS and to identify chromosomal abnormalities with a previously unrecognized good or poor prognosis in 640 patients. In univariate analyses, cases with single 1q abnormalities experienced poor survival, whereas those with trisomy 8 had a higher risk of acute leukaemic transformation than the remaining patients (P = 0.004 and P = 0.009 respectively). Patients with single del(12p) had a similar survival to patients with a normal karyotype and showed some trend for a better survival than other cases belonging to the IPSS intermediate-risk cytogenetic subgroup (P = 0.045). Multivariate analyses demonstrated that IPSS cytogenetic prognostic subgroup, proportion of bone marrow blasts and haemoglobin level were the main prognostic factors for survival, and the first two characteristics and platelet count were the best predictors of acute leukaemic transformation risk. A large international co-operative study should be carried out to clarify these findings.

UI MeSH Term Description Entries
D007140 Immunoglobulin Fab Fragments Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fab Fragment,Fab Fragments,Ig Fab Fragments,Immunoglobulins, Fab Fragment,Fab Immunoglobulin Fragments,Immunoglobulin Fab Fragment,Immunoglobulins, Fab,Fab Fragment Immunoglobulins,Fab Fragment, Immunoglobulin,Fab Fragments, Immunoglobulin,Fragment Immunoglobulins, Fab,Fragment, Fab,Immunoglobulin Fragments, Fab
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002869 Chromosome Aberrations Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS. Autosome Abnormalities,Cytogenetic Aberrations,Abnormalities, Autosome,Abnormalities, Chromosomal,Abnormalities, Chromosome,Chromosomal Aberrations,Chromosome Abnormalities,Cytogenetic Abnormalities,Aberration, Chromosomal,Aberration, Chromosome,Aberration, Cytogenetic,Aberrations, Chromosomal,Aberrations, Chromosome,Aberrations, Cytogenetic,Abnormalities, Cytogenetic,Abnormality, Autosome,Abnormality, Chromosomal,Abnormality, Chromosome,Abnormality, Cytogenetic,Autosome Abnormality,Chromosomal Aberration,Chromosomal Abnormalities,Chromosomal Abnormality,Chromosome Aberration,Chromosome Abnormality,Cytogenetic Aberration,Cytogenetic Abnormality
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
May 1988, American journal of hematology,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
August 1986, Clinics in haematology,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
August 2005, Leukemia,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
April 2009, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
January 2004, Srpski arhiv za celokupno lekarstvo,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
December 2020, Leukemia & lymphoma,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
August 2003, Pathologie-biologie,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
June 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
October 1996, Leukemia & lymphoma,
F Solé, and B Espinet, and G F Sanz, and J Cervera, and M J Calasanz, and E Luño, and F Prieto, and I Granada, and J M Hernández, and J C Cigudosa, and J L Diez, and E Bureo, and M L Marqués, and E Arranz, and R Ríos, and J A Martínez Climent, and T Vallespí, and L Florensa, and S Woessner
September 2014, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
Copied contents to your clipboard!